Armanezumab
Armanezumab is a monoclonal antibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease.
Para uso exclusivo en investigación. No vendemos a pacientes.
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
Species Reactivity
Human
In Vitro
Armanezumab (3-243 nM) binds recombinant human 0N/4R tau protein with a high affinity, characterized by an equilibrium dissociation constant of 38.8 nM[1].
Armanezumab (0.02-12.5 μM; 1.5 h) specifically targets the PRQEF epitope (amino acids 4-8) of tau2-18, with amino acids 6 (glutamine) and 7 (glutamic acid) being essential for binding[1].
Armanezumab (1 μM; 16 h) partially protects SH-SY5Y human neuroblastoma cells from tau oligomer-mediated cytotoxicity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:SH-SY5Y human neuroblastoma cells
-
Concentration:1 μM (Armanezumab pre-incubated with 0.5 μM tau oligomers)
-
Incubation Time:16 h (cell incubation with oligomer-Armanezumab mixture)
-
Result:Restored SH-SY5Y cell viability to 89% compared to 36% viability in cells treated with tau oligomers alone, protecting cells from tau oligomer-mediated cytotoxicity.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:THY-Tau22 tau transgenic mice (6-month-old)[1]
-
Dosage:2 μg
-
Administration:intracranial injection (hippocampus and cortex); single dose
-
Result:Reduced total tau (HT7-stained) and phosphorylated tau species including pThr212, pSer214, pSer396/pSer404 (PHF1-stained), pThr212/pSer214 (AT100-stained), pThr231 (AT180-stained), and pSer202/pThr205 (AT8-stained) in the ipsilateral hemisphere compared to contralateral control IgG-injected hemisphere.
Confirmed neuronal integrity at injection sites via anti-NeuN staining.
Gene ID
Accession
Target
Tau
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Aplicación
ELISA, FACS, Functional assay
Chemical Information
-
SMILES
[Armanezumab]
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Armanezumab Related Classifications
HY-P992057 Related Classifications
Powered by Bioz